CLL
News
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
News
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
News
CLL, MBL had lower response rates to flu vaccination, compared with healthy adults
Patients with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis were assessed for their immune response.
News
Experts offer roadmap for treating CLL during the pandemic
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients
News
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia
The presence of “many or very many nevi [moles]” was particularly associated with the risk of CLL.
News
Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients
Conference Coverage
Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL
News
ESMO offers new clinical practice guideline for CLL